L-Tryptophan Depletion Using a New Bioreactor: A Possible New Cancer Therapy
DOI:
https://doi.org/10.14738/bjhmr.101.13737Keywords:
L-tryptophan, Tryptophan metabolism, L-tryptophan side chain oxidase (TSO), TSO bioreactor, antitumor enzymeAbstract
Not all cancer therapeutic strategies known to date are not adequate for all cancer patients. Most of them are followed by a high rate of severe side effects and complications. L-Tryptophan metabolism plays a key role in organism development, as well as in the occurrence and development of tumors. By degrading certain amino acids, tumor growth can be limited while maintaining the body´s normal nutritional requirements. The L-tryptophan depletion bioreactor is described as a possible new method of cancer therapy. L-tryptophan is an essential amino acid that has been recognized as an important cancer nutrient and its removal can lead to destruction of the tumor cells. Tumor cells or normal human cells cannot synthesize L-tryptophan and therefore tumor resistance is unlikely to develop. L-tryptophan is also a constituent for different bio-molecules such as Serotonin, Melatonin, and is needed for other synthesis processes in the cell growth. L-tryptophan degrading enzymes with three iso-enzymes called tryptophan side chain oxydase (TSO) I, II, III have different molecular weights and different effectiveness. All the TSO enzymes have heme that can catalyze essentially similar reactions involving L-tryptophan as a substrate. The most effective TSO is the type TSO III. A column, which contained TSO, immobilized on silica beats as a bioreactor, was integrated in a plasmapheresis unit and tested it in different animals. In sheep and rabbits, L-tryptophan depletion in plasma was shown at 95% and 100% rates respectively by a single pass through the bioreactor. In 20 different tumor cell lines, there were different efficacies. Brest cancer and medulloblastoma showed the greatest efficacy of L-tryptophan degrading. The gene technology of TSO production from Pseudomonas is associated with formation of endotoxins. These endotoxins must be eliminated. Bioreactors with TSO III are developed to treat cancer diseases successfully, and has low side effects. A combination of L-tryptophan depletion with all available cancer therapies is possible.
References
Xue C, Gu X, Zhao Y, et al. Predictor of hepatocellular carcinoma prognosis and immunotherapeutic effects based on tryptophan metabolism-related genes. Cancer Cell Int. 2022; 22: 308. https://doi.org/10.1186/s12935-022-02730-8.
Modoux M, Rolhion N, Mani S, Sokol H. Tryptophan Metabolism as a Pharmacological Target. Trends Phaamacolog Sci. 2021; 42(1): 60-73.
Badawy AE. Tryptophan metabolism and disposition in cancer biology and immunotherapy. Biosci Rep. 2022; 42(11): BSR 20221682. https://doi.org/10.1042/BSR/20221682.
Liu XH, Zhai XY. Role of tryptophan metabolism in cancers and therapeutic implications. Biochimie. 2021; 182: 131-139.
Piatten M, Friedrich M, Walnwright DA, et al. Tryptophan metabolism in brain tumors. Curr Opin Immunol. 2021; 70:57-66.
Schmer G, Chandler WL. Enzyme Reactors: Achievements, Problems, Future Perspectives. In: Bambauer R, Malchesky PS, Falkenhagen D (Eds.). Therapeutic Plasma exchange and Selective Plasma Separation. Schattauer Verlag, New York, 1987, pp 437-443.
Bambauer R. L-Tryptophan depletion bioreactor: a possible cancer therapy. Am J Exp Res. 2015; 2(3):107-112.
Najafi S, Majidpoor J, Mortezaee K. The impact of microbiota on PD/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life Sciences. 2022; 310: 121138.
Liu H, Xiang Y, Zong QB, et al. TDO2 modulates liver cancer cell migration invasion via the Wnt 5a pathway. Int J Oncol. 2022; https://doi.org/10.3892/ijo.2022.5362.
Shi, D, Wu X, Jian Y, et al. USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer. Nature Communication. 2022; 13: 5644. https://www.nature.com/s41467-022-33285-x.
Reichle A, Diddens H, Rastetter J, Berdel WE. Resistenzmechanismen maligner Zellen gegenüber Zytostatika. Dtsch Med Wschr. 1991; 116:186-191.
Volm M, Mattern J, Samsel B. Häufung von zytostatica-resistenten Lungentumoren bei Rauchern. Dtsch Med Wschr. 1991; 116:1303 -1306.
Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic cast5ation-resistant prostate cancer. Nat Rev Clin Oncol. 2011; 8(1): 12-23.
Lohiya V, Aragon-Ching JB, Sonpavde G. Role of chemotherapy and mechanisms of resistance to chemotherapy in metastatic Castration-resistance. Clin Med Ins: Oncol. 2018; 10(8): 57-66.
Zhang X, Yashiro M, Qui H et al. Establishment and characterization of multidrug-resistant gastric cancer cell lines. Anticancer Res. 2010; 30(3): 915-921.
Qui H, Yashiro M, Zhang X et al. A FGFR2 inhibitor, Ki23057, enhances the chemo sensitivity of drugresistant gastric cancer cells. Cancer Lett. 2011; 307(1):47-52.
Okazaki M, Fushida S, Tsukadia T, et al. The effect of HIF-1α and PKMI expression on acquisition of chemo-resistance. Canc Managem Res. 2018; 10: 1865-1874.
Lüftner D, Possinger K. neue Hpormone und Zytostatika in der Tumortherapie. Internist. 1997; 38: 1037-1044.
Kanz L. Hochdosistherapie und Stammzell Transplantation. Internist 1997; 38:1045-1049.
Schirmacher V. Tumorvakzine und aktiv spezifische Immuntherapie. Internist. 1997; 38:1050-1054.
Gramatzki M, Valerius T. Antikörper als spezifische Tumortherapie. Internist. 1997; 38:1055-1062.
Barth S, Winkler U, Diehl V et al. Immunotoxine. Internist. 1997; 38:1063-1069.
Lindemann A, Mertelsmann R. Gentherapie. Internist. 1997; 38:1070-1073.
Alves P, Hiddemann W. Thyroxinaseinhibitoren. Internist. 1997; 38: 1074-1082.
Wörmann B, Wulf GG, Griesinger F et al. Sensitiver Nachweis disseminierter Tumorzellen. Prognostische Bedeutung und Therapieansätze. Internist. 1997; 38: 1083-1091.
Lentz MR. The role of therapeutic apheresis in the treatment of cancer. A review. Ther Apher. 1993; 3: 40.
Fiedler W, Gehling U, Mende T et al. Neoangiogenese und Tumorwachstum. Dtsch Ärztebl. 2001; 98: A 1392.
Porrata LF, Markowic SN. Therapeutic apheresis immunologic graft engineering for the treatment of cancer. Transplantationsmedizin. 2010; 22:379-382.
Chaturvedi, Vivek K, Singh et al. Cancer Nanotechnology: A New Revolution for Cancer Diagnosis and Therapy: Current Drug Metabolism. 2019; 20(6):416-429.
Rosenfeld HJ, Watanabe AK, Roberts J. Mechanism of action of indolyl-3-alkane-α-hydroxylase. Biol Chem. 1977; 252:6970-6973.
Roberts J Schmid FA, Rosenfeld HJ. Biologic and antineoplastic effects of enzyme-mediated in vivo depletion of L-glutamine, L-tryptophan, and L.-histidine. Cancer Treat Rep. 1979; 63:1045-1054. 128
Cook SJ, Pogson CI, Smith SA. Indoleamine 2,3dioxygenase. Biochem J. 1980; 189:461-466.
Schmer G, Roberts J. Purification of indolyl-3alkane-α-hydroxylase by affinity chromatography on indolyl-agarose columns. Biochim Biophy Acta.1978; 527: 264-271.
Yoshida R, Park SW, Yasul H et al. Tryptophan degration in transplanted tumor cells undergoing rejection. J Immunol. 1988; 141:12819-2823.
Kidd JG. Regression of transplanted lymphoma induced in vive by means of normal guinea pig serum: II. Studies on the nature of the active serum constituent: histological mechanism of regression: tests for effects of guinea pig serum on lymphoma cells in vitro: Discussion. 1953; J Exp Med. 98:565.
Kidd JG. Regression of transplanted lymphoma induced in vivo by means of normal guinea pig serum: II. Studies on the nature of the active serum constituent histological mechanism of regression: tests for effects of guinea pig serum on lymphoma cell in vitro: Discussion. J Exp Med. 1953; 98:583.
Broome JD. Evidence that the L-asparaginase activity in guinea pig serum is responsible for its antilymphoma effects. Nature 1997; 191:114.
Roberts J, Rosenfeld HJ. Isolation, Crystallization and Properties of indolyl-3-alkane-α-Hydroxylase. J Biol Chem. 1977; 252:2640-2647.
Schmer G, Roberts J. Molecular engineering of the L-tryptophan-depleting enzyme indolyl-3-alkane-αhydroxylase. Canc Treat Rep. 1979; 63:1123-1126.
Schmer G, Dennis MB, Hsueh S, Hou KC. The synthesis of L-trytpophan degrading bioreactors. Int J Artif Org.1990; 13:316 -320.
Dennis MB, Jensen WH, Bauermeister U Vienken J, Schmer G. Successful use of a miniaturized plasmapheresis circuit for long-term use in rabbits. Trans Am Soc Artif Int Org. 1988; 34:651-654.
Schmer G. L-Tryptophan degration in animal with cancer and cell-lines. Personal Communication, 2002.
Schmer G, Bambauer R. Die extrakorporale Entfernung von L-Tryptophan mit einem Plasmapherese-Bioreaktorsystem. Dial Journal. 2000;19: 67-69.
Bhutia YD, Babu E, Ganapathy V. Interferon-γ induces a tryptophan-selective amino acid transporter in human colony epithelial cells and mouse dendritic cells. Biochim Biophys Acta-Biomembranes.2015; 1848(2): 453-462.
Bambauer R, Breitbach GP, Haas HJ, Keller HE, Schmer G. L-Tryptophan degrading bioreactor in the treatment of a patient with metastatic cancer. In: Final program of ASFA, Fourteenth Annual meeting, th th April 15 -April 17 1993, Boston, MA, USA.
Yang A, Ben W, Shuai X, Sang L, Yefu W. Tryptophan Side-Chain Oxidase Enzyme suppresses Hepatocellular Carcinoma Growth through Degradation of Tryptophan. Int J Mol Sci. 2021; 22:12428. https://doi.org/10.3390/ifms22221428.
Yefu W. Tryptophan-free Food as a diet for cancer patients. Personal Communication, 2022.
Katarzyna K, Natalia M, Tomasz B. Small molecule Originated from Tryptophan and their Clinical Significance as Potential Biomarkers. Combinatorial Chemistry. 2022; 25(11): 1809-181. https://doi.org/10.2174/1386207325666211216140240.
Liu Y, Xie J, Zhao X, et al. A polymeric IDO inhibitor based on poly (ethylene glycol-b-poly(L-tyrosine-co-1-methyl-D-tryptophan) enables facile trident cancer immunotherapy. Biomaterials Science. 2022; 12. https://pubs.rsc.org/en/content/articleanding/2022/bm/d2bm.
Passarelli A, Pisano C, Cecere, SC, et al. Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer. Frontiers in Immunology. 2022; 13:953115. Doi: 103389/f: mmu.2022.933115.
Jing H, Xiaobo W, Bing l, et al. L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression. J Immunother Cancer:2022; 10(6): e003957. Doi: 10.1136/jitc-2021-003957.
Bambauer R. Tryptophan Depletion Bioreactor, a New Cancer Therapy. Curr Trends Biomedical Eng & Biosci. 2017; 10(4); 555795. Doi: 10.19080/CTBEB.2017.10.555795.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Rolf Bambauer
This work is licensed under a Creative Commons Attribution 4.0 International License.
